What is the definition and pathophysiology of primary splenic non-Hodgkin's lymphoma (NHL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Primary Splenic Non-Hodgkin's Lymphoma: Definition and Pathophysiology

Definition

Primary splenic lymphoma (PSL) is a rare entity defined as lymphomatous involvement limited to the spleen and splenic hilum only, without evidence of nodal or other extrasplenic disease at diagnosis, comprising less than 1-2% of all non-Hodgkin's lymphomas. 1, 2, 3, 4

Diagnostic Criteria

  • Lymphoma must originate within the spleen with involvement restricted to the spleen and splenic hilum (Stage 1-2 disease) 2, 4
  • No biopsy-proven evidence of extrasplenic disease, including liver or lymph nodes, at time of diagnosis 2
  • The definition remains somewhat ambiguous in the literature, with some experts allowing for later metastatic spread while others requiring strict splenic confinement 3, 4

Histologic Subtypes

The most common PSL variants include:

  • Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) 5
  • Splenic marginal zone lymphoma (SMZL) 5
  • Splenic red pulp small B-cell lymphoma 5
  • Splenic hairy cell leukemia variant 5
  • Most PSLs are of B-cell origin, showing low or intermediate-grade histology on pathologic analysis 3

Pathophysiology

Cellular Origin and Development

  • PSL develops from malignant transformation of B-lymphocytes within the splenic white pulp or red pulp compartments 6
  • The spleen, being a major lymphoid organ, provides a microenvironment conducive to lymphoproliferation, though the exact mechanisms triggering primary splenic lymphomagenesis remain poorly understood 5
  • Unlike secondary splenic involvement in disseminated NHL (which is common), PSL represents de novo malignant transformation within splenic tissue 4

Clinical Manifestations

The pathophysiology manifests through:

  • Progressive splenomegaly causing mechanical symptoms including left upper quadrant pain, early satiety, and abdominal distension 2, 3
  • Nonspecific systemic B-symptoms including low-grade fevers, night sweats, and weight loss 3
  • Cytopenias resulting from hypersplenism and bone marrow involvement (when present) 1
  • Rare complications include hemophagocytic lymphohistiocytosis (HLH) with fever, cytopenia, hepatosplenomegaly, hyperferritinemia, and phagocytosis of hematopoietic cells 1
  • Spontaneous splenic rupture can occur, particularly after chemotherapy initiation 1

Epidemiologic Context

  • Non-Hodgkin's lymphoma overall accounts for approximately 4% of all new cancer cases, with PSL representing a small fraction of this burden 7
  • The rarity of PSL (less than 1-2% of NHL cases) makes standardized diagnostic and treatment approaches challenging 1, 2, 3

Diagnostic Challenges

  • Fine-needle aspirate and core needle biopsy of the spleen are not routinely offered at most medical centers, making preoperative diagnosis difficult 5
  • Splenectomy often serves as both diagnostic and therapeutic intervention 2, 5
  • Clinical presentations can be nonspecific, sometimes mimicking other conditions such as nephrolithiasis 3

References

Research

Primary non-Hodgkin lymphoma of the spleen.

American journal of hematology, 1991

Research

Non-Hodgkin's lymphoma of the spleen.

Leukemia & lymphoma, 1993

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Epidemiology of Splenic Lymphoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the treatment approach for primary non-Hodgkin's lymphoma (NHL) of the spleen?
What is the management approach for a patient diagnosed with primary splenic non-Hodgkin lymphoma (NHL)?
What is the treatment approach for a patient with primary splenic non-Hodgkin's lymphoma?
What are the clinical features of primary splenic non-Hodgkin's lymphoma?
What is the initial treatment approach for a patient with Non-Hodgkin's Lymphoma (NHL) of the spleen?
Could the recent addition of buspirone (an anxiolytic) and increased dose of sertraline (a selective serotonin reuptake inhibitor) be causing my gastrointestinal distress, sexual side effects, restlessness, and insomnia, 8 days after starting the combination and 5 days after adding 15mg of buspirone daily?
Is negative skin testing recommended for pediatric dental patients with a history of allergies or suspected allergies?
What is the recommended dose and infusion protocol for Rituximab (rituximab) in patients with non-Hodgkin's lymphoma or rheumatoid arthritis?
What is the management plan for a patient with subcutaneous emphysema at incision sites following a recent thoracic or abdominal surgical procedure?
What is the recommended treatment for a patient with Neuromyelitis Optica (NMO) aquaporin antibody disease?
What are the pros and cons of switching from sertraline to fluvoxamine in a patient with autism, social anxiety, GAD, OCD, and ADHD, currently taking sertraline, buspirone, guanfacine, and viloxazine, with a history of reduced dopamine at lower sertraline doses and ongoing side effects?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.